background
approxim
million
death
cardiovascular
diseas
occur
everi
year
half
due
acut
myocardi
infarct
ami
occur
lowand
middleincom
countri
therefor
lowcost
therapi
would
invalu
although
glucoseinsulinpotassium
gik
infus
lowmolecularweight
heparin
lmwh
appear
promis
ami
avail
trial
inconclus
treatment
requir
rigor
evalu
evaluationestudio
latino
america
createecla
studi
random
control
trial
stelev
ami
patient
evalu
infus
glucoseinsulinpotassium
gik
intraven
vs
usual
care
control
mortal
patient
countri
patient
india
china
n
also
random
use
factori
design
receiv
lowmolecularweight
heparin
reviparin
placebo
inject
twice
daili
day
assess
impact
composit
outcom
death
reinfarct
stroke
first
coprimari
outcom
composit
refractori
ischemia
second
coprimari
outcom
twenti
thousand
two
hundr
one
gikcontrol
patient
reviparinplacebo
patient
includ
result
expect
novemb
createecla
trial
provid
definit
answer
role
practic
promis
lowcost
therapi
lmwh
gik
ami
patient
effect
therapi
could
use
small
medic
center
lowand
middleincom
countri
experi
trial
indic
larg
trial
import
question
success
conduct
resourcepoor
set
academ
group
without
industri
involv
heart
j
see
relat
editori
page
approxim
million
death
cardiovascular
diseas
cvd
occur
everi
year
half
due
acut
myocardi
infarct
ami
occur
lowand
middleincom
countri
lic
mic
especi
indian
subcontin
china
aspirin
thrombolyt
therapi
angiotensin
convert
enzym
ace
inhibitor
improv
prognosi
ami
adopt
wide
recent
trial
suggest
primari
percutan
coronari
angioplasti
pci
offer
benefit
thrombolyt
therapi
rapid
access
primari
pci
limit
part
world
combin
newer
antiplatelet
regimen
direct
thrombin
inhibitor
yield
clear
increment
benefit
caus
increas
bleed
although
heparin
commonli
use
ami
especi
patient
receiv
fibrinspecif
thrombolyt
agent
trial
lowmolecularweight
heparin
lmwh
appear
promis
convinc
evid
agent
reduc
mortal
patient
receiv
thrombolyt
therapi
aspirin
tabl
ii
ii
b
although
lmwh
reduc
reinfarct
appear
impact
mortal
furthermor
signific
increas
major
bleed
trend
toward
hemorrhag
stroke
agent
tabl
ii
ii
b
therefor
net
benefitrisk
ratio
clear
larger
trial
blind
one
exclud
potenti
bias
ascertain
outcom
involv
judgement
eg
earli
reinfarct
uncertainti
net
benefit
risk
lmwh
reflect
clear
recommend
use
thrombin
inhibitor
ami
especi
receiv
thrombolyt
agent
fibrinspecif
although
ufh
wide
use
fibrinspecif
thrombolyt
agent
base
improv
coronari
arteri
patenc
small
trial
power
reliabl
assess
impact
clinic
outcom
death
reinfarct
bleed
stroke
therefor
larg
definit
trial
lmwh
vs
placebo
urgent
need
metabol
modul
ami
glucoseinsulinpotassium
gik
infus
propos
gik
suppress
myocardi
uptak
free
fatti
acid
therebi
reduc
myocardi
oxygen
requir
improv
ventricular
contractil
also
increas
intramyocellular
potassium
effect
may
reduc
lifethreaten
arrhythmia
improv
ventricular
remi
reinfarct
tt
thrombolyt
therapi
sk
streptokinas
odd
ratio
confid
interv
ci
calcul
use
yusufpeto
modif
mantelhaenszel
method
function
could
reduc
mortal
metaanalysi
small
trial
involv
almost
patient
indic
relativerisk
reduct
mortal
p
wide
ci
tabl
iii
figur
howev
trial
evalu
high
dose
glucos
insulin
report
relativerisk
reduct
rrr
mortal
p
compar
nonsignific
rrr
lowdos
gik
trial
anted
thrombolyt
agent
aspirin
incomplet
followup
lack
inform
integr
random
although
encourag
larg
definit
trial
gik
context
modern
manag
ami
requir
despit
low
cost
gik
potenti
global
applic
larg
trial
question
yet
done
perhap
lack
commerci
interest
complex
rule
hamper
conduct
larg
trial
academicallydriven
question
littl
extern
fund
last
year
group
us
sever
countri
decid
perform
similar
trial
creat
trial
ecla
trial
estudio
latin
america
studi
group
aim
reliabl
evalu
role
highdos
gik
patient
addit
india
china
creat
simultan
evalu
lmwh
reviparin
subject
although
trial
design
initi
separ
given
substanti
similar
gik
compon
earli
decis
made
merg
standard
trial
reliabl
evalu
gik
describ
design
studi
baselin
characterist
discuss
challeng
face
establish
trial
creat
trial
initi
investig
canada
china
india
without
extern
fund
util
opportunist
meet
intern
fund
popul
health
research
institut
phri
mcmaster
univers
hamilton
health
scienc
studi
design
simpl
data
collect
parsimoni
focus
major
clinic
outcom
emphas
data
qualiti
adher
studi
regimen
facilit
train
investig
data
entri
internet
central
data
review
central
event
adjud
key
outcom
judici
onsit
monitor
gik
primari
outcom
reduct
mortal
compar
usual
care
reviparin
compar
placebo
coprimari
outcom
first
coprimari
outcom
composit
death
mi
stroke
day
second
coprimari
outcom
includ
sever
ischemia
ecg
chang
day
creat
trial
util
partial
factori
design
compar
reviparin
lowmolecularweight
heparin
placebo
given
day
discharg
remi
reinfarct
nr
record
tt
thrombolyt
therapi
tpa
tissu
plasminogen
activ
abx
abciximab
tnk
tenecteplas
odd
ratio
confid
interv
ci
calcul
use
yusufpeto
modif
mantelhaenszel
method
discharg
earlier
day
doubl
blind
gik
vs
control
open
given
hour
patient
india
china
random
part
trial
n
patient
wherea
pakistan
includ
gik
compon
total
patient
patient
present
suspect
ami
stsegment
elev
new
left
bundl
branch
block
within
hour
symptom
onset
without
contraind
heparin
gik
provid
written
consent
wit
oral
consent
random
figur
studi
design
flow
chart
recommend
studi
glucoseinsulinpotassium
prepar
ad
iu
insulin
regular
human
mmol
kcl
ml
bag
glucos
infus
dedic
peripher
intraven
iv
site
rate
mlkgh
hour
regimen
ident
ecla
pilot
patient
random
control
group
receiv
usual
care
glucos
potassium
sodium
level
check
baselin
hour
hour
adjust
rate
infus
gik
allow
base
blood
glucos
potassium
level
killip
class
statu
patient
fluid
intak
output
first
hour
record
subject
aspect
patient
manag
discret
local
treat
physician
center
european
pharmacopoeia
measur
ph
eur
lmwhbrp
standard
overal
result
trial
gik
vs
control
allcaus
inhospit
mortal
trial
ceremuzynski
measur
outcom
day
data
individu
trial
combin
util
modifi
mantelhaenszel
method
createecla
partial
factori
studi
design
obtain
local
ethic
committe
approv
addit
project
offic
obtain
approv
institut
review
board
hamilton
health
scienc
mcmaster
univers
hamilton
canada
ecla
group
independ
complet
pilot
trial
promis
result
highdos
gik
util
highdos
gik
regimen
main
ecla
trial
initi
latin
america
later
expans
kuwait
europ
usa
australasia
compon
recruit
patient
given
ident
natur
gik
regimen
creat
ecla
primari
outcom
mortal
similar
datacollect
trial
trial
merg
novemb
evalu
gik
ensur
patient
would
random
harmon
key
aspect
definit
data
collect
etc
studi
occur
studi
involv
center
china
india
pakistan
argentina
brazil
kuwait
venezuela
north
america
europ
data
center
china
sent
mail
nation
center
nc
beij
indian
center
nc
bangalor
pakistani
center
nc
karachi
center
ecla
offic
rosario
argentina
region
coordin
center
enter
data
webbas
oracl
databas
ecla
connect
onlin
popul
health
research
institut
phri
hamilton
canada
extens
consist
edit
check
centralev
adjud
ensur
high
data
qualiti
data
ecla
trial
transfer
phri
regular
interv
addit
data
check
conduct
prior
statist
analys
report
independ
data
safeti
monitor
board
dsmb
form
join
board
set
trial
one
member
ecla
dsmb
yusuf
step
joint
board
soon
studi
combin
remain
blind
subsequ
data
time
subject
review
ecla
dsmb
newli
constitut
board
period
review
accumul
data
efficaci
safeti
three
formal
interim
analys
occur
data
avail
first
look
boundari
benefit
sd
p
mortal
gik
first
coprimari
outcom
reviparin
third
look
boundari
p
deviat
boundari
remain
cross
success
examin
data
month
apart
ensur
robust
consist
result
anticip
rate
day
placebo
group
first
coprimari
outcom
death
mi
stroke
patient
would
power
detect
relativerisk
reduct
reviparin
gik
comparison
death
rate
day
control
group
subject
would
power
detect
rrr
power
detect
rrr
tabl
iv
summar
key
baselin
characterist
two
third
patient
random
hour
symptom
onset
patient
killip
class
evid
heart
failur
baselin
glucos
level
mmoll
potassium
meql
thrombolyt
therapi
use
primari
pci
rate
reperfus
therapi
higher
india
compar
china
patient
india
china
prerandom
heparin
given
patient
nonstudi
heparin
random
use
patient
reviparin
match
placebo
given
individ
gust
gust
juli
ual
gik
given
patient
random
gik
aspirin
use
clopidogrel
ace
inhibitor
lipidlow
medic
ecla
inform
collect
calcium
channel
blocker
thu
high
proport
patient
receiv
proven
pharmacolog
therapi
excel
adher
alloc
studi
treatment
studi
formid
undertak
success
recruit
overal
target
patient
lack
extern
fund
requir
investig
meet
gener
attach
meet
although
annual
region
meet
held
india
china
center
ecla
provid
compens
center
creat
india
china
pakistan
receiv
modest
compens
per
patient
cover
visibl
cost
despit
last
year
studi
recruit
rate
averag
patient
per
year
nation
coordin
center
obtain
nation
regulatori
approv
licenc
drug
import
process
extrem
bureaucrat
slow
month
countri
chiefli
design
done
pharmaceut
compani
independ
contract
research
organ
cro
consider
expens
quot
cro
india
obtain
approv
monitor
trial
exceed
entir
cost
run
studi
india
note
countri
streamlin
effici
mechan
obtain
regulatori
approv
studi
conduct
independ
industri
sever
particip
center
institut
review
board
irb
ethic
committe
nation
independ
irb
use
consider
initi
delay
receiv
packag
drug
reviparinplacebo
compani
midst
takeov
studi
consid
suffici
high
prioriti
within
new
organ
center
nr
record
high
rate
use
thienopyrid
due
avail
combin
tablet
aspirin
clopidogrel
creat
studi
first
trial
particip
consider
train
small
studi
meet
phone
need
despit
enthusiasm
rel
simplic
studi
center
initi
problem
accur
complet
form
compli
certain
aspect
studi
protocol
maintain
care
document
therefor
institut
system
onsit
monitor
train
train
staff
site
creat
provid
support
improv
protocol
adher
data
qualiti
consider
random
india
studi
initi
use
seal
envelop
due
lack
lowcost
reliabl
access
telephon
line
hoursaday
hospit
despit
multipl
safeguard
alloc
error
occur
patient
therefor
despit
higher
cost
random
switch
central
telephon
system
bangalor
india
substanti
reduc
alloc
error
rate
china
central
random
use
throughout
error
occur
given
center
compens
modestli
studi
repeatedli
threaten
withdraw
center
wish
particip
compet
trial
sponsor
pharmaceut
compani
higher
rate
compens
substanti
slow
recruit
ecla
instead
origin
target
patient
year
patient
random
year
less
problem
india
china
center
stop
random
end
particip
trial
nevertheless
center
made
import
contribut
trial
epidem
sever
acut
respiratori
syndrom
sar
china
advers
affect
recruit
sever
particip
hospit
close
stop
admit
ami
patient
lesson
learn
createecla
experi
collabor
first
import
gener
question
incorpor
simpl
protocol
suffici
number
physician
still
will
abl
collabor
littl
reimburs
second
merger
creat
ecla
possibl
longstand
previou
collabor
investig
group
mutual
commit
share
credit
led
ensur
statist
robust
reliabl
result
regard
gik
rather
potenti
inconclus
result
ecla
studi
alon
third
bureaucrat
hurdl
conduct
trial
india
china
formid
took
month
overcom
chiefli
tenac
determin
dedic
nation
coordin
beij
bangalor
fourth
even
simpl
trial
streamlin
sensibl
help
support
oppos
polic
monitor
could
help
improv
studi
qualiti
especi
center
previous
particip
trial
fifth
much
increas
regulatori
bureaucraci
impos
guidelin
good
clinic
practic
guidelin
may
enhanc
qualiti
studi
improv
patient
safeti
care
attent
key
aspect
studi
design
conduct
proper
random
complet
unbias
outcom
ascertain
period
review
data
independ
dsmb
fact
danger
wellintent
guidelin
could
prevent
conduct
import
lowcost
academ
trial
gener
nonpharmaceut
question
impos
burdensom
expens
process
may
littl
scientif
medic
ethic
valu
sixth
peer
review
government
organ
develop
mechan
support
intern
trial
epidemiolog
studi
current
fund
mechan
gener
support
studi
multipl
countri
especi
lowor
middleincom
countri
conclus
createecla
trial
provid
definit
answer
regard
valu
practic
promis
therapi
lmwh
gik
ami
therapi
proven
effect
could
use
even
small
medic
center
lowand
middleincom
countri
practic
experi
conduct
trial
indic
larg
trial
import
question
success
conduct
resourcepoor
set
academ
group
without
industri
involv
howev
studi
uncommon
therefor
larg
number
import
question
remain
unaddress
emphas
need
develop
fund
structur
regul
facilit
global
lowcost
trial
import
public
health
question
